We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Efficacy and Safety of MCS-2 in the Treatment of Lower Urinary Tract Symptoms (MCS_LUTS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01002664
Recruitment Status : Completed
First Posted : October 27, 2009
Last Update Posted : August 2, 2016
Information provided by (Responsible Party):
Health Ever Bio-Tech Co., Ltd.

Brief Summary:
The hypothesis of the study is to examine whether MCS-2 is safe and effective in the treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia.

Condition or disease Intervention/treatment Phase
Lower Urinary Tract Symptoms Benign Prostatic Hyperplasia Drug: MCS-2 Drug: Placebo Phase 3

Detailed Description:
Eligible male subjects will be randomized to receive either MCS-2 or placebo for 12 weeks. Subjects are those not currently on any medicines for BPH or LUTS. During and at the end of the 12-week treatment period, randomized subjects will be evaluated for efficacy and safety parameters. All subjects will be advised to maintain a normal diet, similar to what was consumed before joining the study.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 272 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase III, Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Efficacy and Safety of MCS-2 in Treating Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia in Treatment Naïve Male Subjects
Study Start Date : May 2010
Primary Completion Date : June 2014
Study Completion Date : June 2014

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Active Comparator: MCS-2
Drug Name: MCS-2 Dosage: 2 soft-gel capsules Frequency: Qd per day after dinner Duration: 12 weeks
Drug: MCS-2
30 mg/day (two 15 mg capsules) Qd for 12 weeks
Other Name: MUS
Placebo Comparator: Placebo
Drug Name: MCS-2 placebo Dosage: 2 soft-gel capsules Frequency: Qd per day after dinner Duration: 12 weeks
Drug: Placebo
2 soft-gel placebo capsules Qd for 12 weeks
Other Name: MCS Matching Placebo

Primary Outcome Measures :
  1. Changes in total International Prostate Symptom Scores (I-PSS) [ Time Frame: 12 weeks ]

Secondary Outcome Measures :
  1. Changes in I-PSS subscores [ Time Frame: 12 weeks ]
  2. Changes in I-PSS quality of life index [ Time Frame: 12 weels ]
  3. Changes in urinary peak flow rate [ Time Frame: 12 weeks ]
  4. Incidence of treatment-emergent adverse events [ Time Frame: 12 weeks ]
  5. Incidence of withdrawals due to treatment-emergent adverse events [ Time Frame: 12 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   40 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age ≧ 40 years old.
  • Not being treated for BPH or LUTS.
  • PSA ≦ 4 ng/ml and no pathologically-proven prostate cancer.
  • I-PSS ≥ 10
  • No known malignancy
  • AST/ALT ≦ 3X UNL.
  • Creatinine ≦ 3X UNL.
  • Subjects who sign the informed consent form.

Exclusion Criteria:

  • Subjects' LUTS are not BPH-related
  • Have been treated with pelvis irradiation or pelvic surgery.
  • Plan to undergo any invasive procedures within the study period.
  • Active infection or inflammation.
  • Considered ineligible by the investigators.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01002664

National Taiwan University Hospital
Taipei, Taiwan, 10002
Sponsors and Collaborators
Health Ever Bio-Tech Co., Ltd.
Principal Investigator: Yeong-Shiau Pu, MD PhD National Taiwan University Hospital

Responsible Party: Health Ever Bio-Tech Co., Ltd.
ClinicalTrials.gov Identifier: NCT01002664     History of Changes
Other Study ID Numbers: MCS-2-TWN-a
First Posted: October 27, 2009    Key Record Dates
Last Update Posted: August 2, 2016
Last Verified: March 2015
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by Health Ever Bio-Tech Co., Ltd.:
Benign Prostatic Hyperplasia
Lower Urinary Tract Symptoms
International prostate symptom scores

Additional relevant MeSH terms:
Prostatic Hyperplasia
Lower Urinary Tract Symptoms
Pathologic Processes
Prostatic Diseases
Genital Diseases, Male
Urological Manifestations
Signs and Symptoms